<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="876">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149755</url>
  </required_header>
  <id_info>
    <org_study_id>D00411092</org_study_id>
    <nct_id>NCT05149755</nct_id>
  </id_info>
  <brief_title>Evolut™ EXPAND TAVR II Pivotal Trial</brief_title>
  <official_title>Evolut™ EXPAND TAVR II Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR&#xD;
      System to include patients with moderate, symptomatic AS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, international, prospective, randomized study. Subject's will be randomized to&#xD;
      either transcatheter aortic valve replacement (TAVR) with the Evolut PRO+ TAVR System and&#xD;
      guideline-directed management (GDMT) or GDMT alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2034</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality, all-stroke, life threatening or fatal bleeding, acute kidney injury, hospitalization due to device or procedure-related complication, or valve dysfunction requiring reintervention</measure>
    <time_frame>30 days</time_frame>
    <description>Life threatening or fatal bleeding is defined as BARC Type 3 or 4 and acute kidney injury is defined as VARC-3 Stage IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of all-cause mortality, heart failure event, or aortic valve replacement or reintervention</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects alive and with moderately improved quality of life (≥ 10 points in KCCQ summary score from baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality and heart failure events (inclusive of hospitalizations)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality, all-stroke, or unplanned CV hospitalizations (inclusive of all aortic valve replacement (AVR))</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure events (inclusive of hospitalizations)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned cardiovascular hospitalizations (exclusive of AVR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and free of unplanned cardiovascular hospitalizations (inclusive of all AVR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <condition>Moderate Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Medtronic Evolut PRO+ TAVR System and guideline-directed management and therapy (GDMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical site determined guideline-directed management and therapy (GDMT) alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Evolut PRO+ TAVR System and guideline-directed management and therapy (GDMT)</intervention_name>
    <description>Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with an Evolut PRO+ TAVR heart valve and given clinical site determined guideline-directed management and therapy (GDMT).</description>
    <arm_group_label>Medtronic Evolut PRO+ TAVR System and guideline-directed management and therapy (GDMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Moderate AS, defined as follows by transthoracic echo (TTE) at rest:&#xD;
&#xD;
               -  Max aortic velocity ≥ 3.0 m/sec and &lt; 4.0 m/sec, and&#xD;
&#xD;
               -  Mean aortic gradient ≥ 20.0 mmHg and &lt; 40.0 mmHg, and&#xD;
&#xD;
               -  AVA &gt;1.0 cm2 and &lt; 1.5 cm2&#xD;
&#xD;
          -  NYHA class ≥ II and symptoms of AS, including but not limited to:&#xD;
&#xD;
               -  Dyspnea at rest or on exertion&#xD;
&#xD;
               -  Fatigue&#xD;
&#xD;
               -  Angina&#xD;
&#xD;
               -  Syncope in the absence of another identifiable cause&#xD;
&#xD;
          -  LVEF &gt; 20% by 2-D echo&#xD;
&#xD;
          -  Any of the following&#xD;
&#xD;
               -  HF event or hospitalization within 1 calendar year prior to qualifying echo&#xD;
&#xD;
               -  NT proBNP ≥ 600 pg/ml (or BNP 80 pg/ml) measured within 6 months prior to or&#xD;
                  within 2 weeks after qualifying echo,&#xD;
&#xD;
               -  Global longitudinal strain ≤15% (absolute value) at qualifying echo, or&#xD;
&#xD;
               -  E/e' (average of medial and lateral velocities) ≥ 14.0 at qualifying echo&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 65 years&#xD;
&#xD;
          -  Class I indication for cardiac surgery&#xD;
&#xD;
          -  Sievers Type 0 or Type 2 bicuspid aortic valve or Sievers Type 1 bicuspid aortic valve&#xD;
             with ascending aorta diameter &gt; 4.5 cm&#xD;
&#xD;
          -  Not anatomically suitable for transfemoral TAVR&#xD;
&#xD;
          -  In need of and suitable for coronary revascularization per Heart Valve Team&#xD;
&#xD;
          -  Documented history of cardiac amyloidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sorajja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allina Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation IUCPQ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Windecker, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital, Universitätsspital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Judkins</last_name>
    <phone>+17635149752</phone>
    <email>morgan.l.judkins@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hang Nguyen</last_name>
    <email>hang.t.nguyen@medtronic.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic</keyword>
  <keyword>stenosis</keyword>
  <keyword>symptomatic</keyword>
  <keyword>moderate</keyword>
  <keyword>valve</keyword>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

